ArticleTropical medicine and health2026
Divergent prognostic roles and risk determinants of myocardial injury in SFTS and HFRS.
Article in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThis study explored the role of myocardial injury in the prognostic assessment of severe fever with thrombocytopenia syndrome (SFTS) and hemorrhagic fever with renal syndrome (HFRS) patients, and analyzed its risk factors.
methodsA retrospective study included 188 SFTS and 101 HFRS patients (2020-2024) from two hospitals. Epidemiological, clinical, and laboratory data were dynamically recorded and statistically analyzed.
resultsSFTS patients were older (65.35 ± 11.04 vs. 53.26 ± 14.66 years) and had more females (56.90% vs. 26.70%, both P < 0.001). HFRS was more likely to present early symptoms (myalgia, fatigue/anorexia, abdominal pain, diarrhea, vomiting, skin petechiae/ecchymosis, headache; all P ≤ 0.040). SFTS mortality (19.70%, 37/188) was significantly higher than HFRS (4.00%, 4/101, P < 0.001). Both groups had elevated myocardial markers (ALT, AST, CK, CK-MB, cTn, LDH, α-HBDH): HFRS had higher levels during days 3-7 (which then decreased), while SFTS levels increased and exceeded those of HFRS during days 8-14. SFTS patients with myocardial injury had higher mortality (29.10% vs. 11.80%, P = 0.003), but HFRS showed no mortality difference between those with and without myocardial injury (P = 0.952). Myocardial injury risk factors emerged in both groups during days 3-7, increased during days 8-14, peaking on day 10 (SFTS) and days 6/12/13 (HFRS).
conclusionSFTS has a higher mortality rate. Myocardial injury is common and early in both groups: HFRS patients show rapid recovery, while SFTS patients experience worsening injury associated with death. Early intervention targeting risk factors is key to reducing mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.